Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Change in Cash (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Change in Cash readings, the most recent being -$11.2 million for Q4 2025.

  • On a quarterly basis, Change in Cash fell 121.19% to -$11.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$118.6 million, a 193.27% decrease, with the full-year FY2025 number at -$118.6 million, down 193.27% from a year prior.
  • Change in Cash hit -$11.2 million in Q4 2025 for Avalo Therapeutics, up from -$15.3 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $102.8 million in Q1 2024 to a low of -$82.7 million in Q2 2025.
  • Median Change in Cash over the past 5 years was -$6.7 million (2022), compared with a mean of -$150050.0.
  • Biggest five-year swings in Change in Cash: plummeted 1444.51% in 2022 and later skyrocketed 2784.25% in 2024.
  • Avalo Therapeutics' Change in Cash stood at -$17.0 million in 2021, then soared by 77.35% to -$3.9 million in 2022, then increased by 28.33% to -$2.8 million in 2023, then skyrocketed by 2004.7% to $52.7 million in 2024, then crashed by 121.19% to -$11.2 million in 2025.
  • The last three reported values for Change in Cash were -$11.2 million (Q4 2025), -$15.3 million (Q3 2025), and -$82.7 million (Q2 2025) per Business Quant data.